BLCO Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of 42.95%. Bausch + Lomb Corp.'s return on equity of -4.53% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Bausch + Lomb Corp. has a consensus price target of $17.25, signalling upside risk potential of 1.59%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 5.15%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Bausch + Lomb Corp., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Bausch + Lomb Corp..

Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Bausch + Lomb Corp. quarterly revenues are $1.3B, which are larger than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Bausch + Lomb Corp.'s net income of -$25M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.21x versus 8.41x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Cooper Cos., Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of 7.94%. Bausch + Lomb Corp.'s return on equity of -4.53% beat The Cooper Cos., Inc.'s return on equity of 4.56%.

Bausch + Lomb Corp. has a consensus price target of $17.25, signalling upside risk potential of 1.59%. On the other hand The Cooper Cos., Inc. has an analysts' consensus of $90.50 which suggests that it could grow by 11.67%. Given that The Cooper Cos., Inc. has higher upside potential than Bausch + Lomb Corp., analysts believe The Cooper Cos., Inc. is more attractive than Bausch + Lomb Corp..

Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cooper Cos., Inc. has a beta of 1.048, suggesting its more volatile than the S&P 500 by 4.779%.

Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. The Cooper Cos., Inc. pays out -- of its earnings as a dividend.

Bausch + Lomb Corp. quarterly revenues are $1.3B, which are larger than The Cooper Cos., Inc. quarterly revenues of $1.1B. Bausch + Lomb Corp.'s net income of -$25M is lower than The Cooper Cos., Inc.'s net income of $84.6M. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while The Cooper Cos., Inc.'s PE ratio is 43.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.21x versus 3.96x for The Cooper Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edesa Biotech, Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.53% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Bausch + Lomb Corp. has a consensus price target of $17.25, signalling upside risk potential of 1.59%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 640.74%. Given that Edesa Biotech, Inc. has higher upside potential than Bausch + Lomb Corp., analysts believe Edesa Biotech, Inc. is more attractive than Bausch + Lomb Corp..

Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Bausch + Lomb Corp. quarterly revenues are $1.3B, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$25M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.21x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.53% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Bausch + Lomb Corp. has a consensus price target of $17.25, signalling upside risk potential of 1.59%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.59 which suggests that it could grow by 437.6%. Given that Oncolytics Biotech, Inc. has higher upside potential than Bausch + Lomb Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Bausch + Lomb Corp..

Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Bausch + Lomb Corp. quarterly revenues are $1.3B, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$25M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.21x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.